Ivana Gojo is an Oncology physician affiliated with Johns Hopkins University. OpenAlex indexes 270 publications with 9,550 citations (h-index 53); ClinicalTrials.gov lists 8 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
600 N Wolfe St
Baltimore, MD 212870005
Telephone
410-955-9441Provider last certified this registry record 16 Mar 2026.
Clinical trials
- Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia
Sponsor: National Cancer Institute (NCI)
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- TAIHO ONCOLOGY, INC.Program year20252 payments
- Geron CorporationProgram year20253 payments
- Astellas Pharma US IncProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
50.3%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor36.4%Valacyclovir100%Part D≥14 patientsShort-acting sulfonamides7.3%Sulfamethoxazole-Trimethoprim100%Part D<11 patients+ 1 more class in this area
Cancer & immunology
17.6%Isocitrate Dehydrogenase 2 Inhibitor9.7%Idhifa100%Part D<11 patientsBCL-2 Inhibitor7.9%Venclexta100%Part D<11 patientsAntiparasitic
9.1%Antimalarial9.1%Atovaquone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2007–2019 per NIH RePORTER. The latest:
- The Johns Hopkins Translational Science Team for the ET-CTN
Johns Hopkins University
FY2019$1,639,503UM1CA186691 - The Johns Hopkins Translational Science Team for the ET-CTN
Johns Hopkins University
FY2018$2,209,015UM1CA186691 - The Johns Hopkins Translational Science Team for the ET-CTN
Johns Hopkins University
FY2017$300,000UM1CA186691
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2023 - Immune dysfunction signatures predict outcomes and define checkpoint blockade–unresponsive microenvironments in acute myeloid leukemia
Journal of Clinical Investigation
2022 - NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022
Journal of the National Comprehensive Cancer Network
2022 - NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021
Journal of the National Comprehensive Cancer Network
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Roger Blumenthal, MD
Johns Hopkins University
Erin Michos, MD
Johns Hopkins University
Morgan Grams, MD
Johns Hopkins University
Mario Eisenberger, MD
Johns Hopkins University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”